<DOC>
	<DOC>NCT00525330</DOC>
	<brief_summary>To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.</brief_summary>
	<brief_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Age 18 to 70 years, inclusive; 2. Males and females of nonchildbearing potential; 3. Diagnosis of type 2 diabetes mellitus according; and 4. On a stable dose of metformin monotherapy at randomization (can be on other oral therapies or naive at study entry 1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia; 2. History or presence of alcoholism or drug abuse 3. Typical consumption of â‰¥10 drinks of alcohol weekly; 4. Presence of any of the following conditions: Significant renal impairment (glomerular filtration rate &lt;60 mL/min [to be calculated by the central laboratory]); Diabetic retinopathy; Diabetic gastroparesis; Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease; 5. Uncontrolled high blood pressure; 6. History or evidence of cardiovascular or pulmonary disease 7. Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>